Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis

Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis

The aim was to summarize pneumococcal disease burden data among adults in Southern Europe and the potential impact of vaccines on epidemiology. Of 4779 identified studies, 272 were selected. Invasive pneumococcal disease (IPD) incidence was 15.08 (95% CI 11.01–20.65) in Spain versus 2.56 (95% CI 1.5...

Full description

Bibliographic Details
Main Authors:	Adoración Navarro-Torné, Eva Agostina Montuori, Vasiliki Kossyvaki, Cristina Méndez
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-10-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	pneumococcal disease burden pneumococcal vaccine pcv13 incidence surveillance adults spain italy greece portugal
Online Access:	http://dx.doi.org/10.1080/21645515.2021.1923348

Similar Items

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review
by: Rita Teixeira, et al.
Published: (2023-05-01)

Hospitalizations for pneumonia, invasive diseases and otitis in Tuscany (Italy), 2002-2014: Which was the impact of universal pneumococcal pediatric vaccination?
by: Sara Boccalini, et al.
Published: (2017-02-01)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
by: Stephanie Perniciaro, et al.
Published: (2021-08-01)

Increased Invasive Pneumococcal Disease, North East England, UK
by: Catherine Houseman, et al.
Published: (2017-01-01)

Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden
by: Karin Bergman, et al.
Published: (2021-08-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
by: Sophie Warren, et al.
Published: (2023-08-01)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
by: Michele Wilson, et al.
Published: (2023-06-01)

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
by: Liping Huang, et al.
Published: (2023-02-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019-04-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
by: Johnna Perdrizet, et al.
Published: (2023-04-01)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
by: Strutton David R, et al.
Published: (2012-08-01)

Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
by: Sergi Hernández, et al.
Published: (2020-07-01)

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
by: Arijita Deb, et al.
Published: (2022-09-01)

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
by: Nobuhiro Asai, et al.
Published: (2021-11-01)

Impact of Demographic Developments and PCV13 Vaccination on the Future Burden of Pneumococcal Diseases in Germany—An Integrated Probabilistic Differential Equation Approach
by: Myka Harun Sarajan, et al.
Published: (2024-03-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)

Vaccine prophylaxis of pneumococcal infection among premature infants with bronchopulmonary dysplasia
by: Vladislav SEMERICOV, et al.
Published: (2020-03-01)

Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
by: Rosario Menéndez, et al.
Published: (2023-11-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
by: Yasunori Ishihara, et al.
Published: (2023-01-01)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
by: Yan Li, et al.
Published: (2021-11-01)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022-01-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)

Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis
by: Tianyan Hu, et al.
Published: (2023-04-01)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012–2018
by: Larisa Savrasova, et al.
Published: (2021-10-01)

Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations
by: Seong-Beom Park, et al.
Published: (2019-06-01)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
by: Sarah J. Pugh, et al.
Published: (2018-12-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016–2020)
by: Ruth Gil-Prieto, et al.
Published: (2023-01-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Low Adherence to Pneumococcal Vaccination in Lung Cancer Patients in a Tertiary Care University Hospital in Southern Germany
by: Arno Mohr, et al.
Published: (2022-02-01)

A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
by: Hamaguchi M, et al.
Published: (2023-05-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths
by: Robert Root-Bernstein
Published: (2021-05-01)

Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
by: Claire von Mollendorf, et al.
Published: (2024-03-01)

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
by: Ashleigh McGirr, et al.
Published: (2018-11-01)